Skip to main content
. 2022 May 26;7(8):1831–1841. doi: 10.1016/j.ekir.2022.05.017

Figure 1.

Figure 1

Patient disposition in the JANUS study. Of the 8 patients who discontinued treatment, 5 completed the safety follow-up period of 24 weeks (placebo, n = 2; atacicept 25 mg, n = 2; atacicept 75 mg, n = 1) and 1 patient completed a safety follow-up period of 12 weeks (placebo group). ∗Both due to study termination by sponsor. ∗∗One due to study termination by sponsor, one due to withdrawal from the study.